Literature DB >> 17443327

Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.

David Chu1, Michelle Stevens, Douglas Edward Gladstone.   

Abstract

A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17443327     DOI： 10.1007/s00296-007-0354-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Morie A Gertz; Athanasios Anagnostopoulos; Kenneth Anderson; Andrew R Branagan; Morton Coleman; Stanley R Frankel; Sergio Giralt; Todd Levine; Nikhil Munshi; Alan Pestronk; Vincent Rajkumar; Steven P Treon
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Evaluation of cryoglobulins.

Authors:  U Kallemuchikkal; P D Gorevic
Journal:  Arch Pathol Lab Med       Date:  1999-02       Impact factor: 5.534

3.  Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

Authors:  Stanley I Martin; Francisco M Marty; Karen Fiumara; Steven P Treon; John G Gribben; Lindsey R Baden
Journal:  Clin Infect Dis       Date:  2006-05-17       Impact factor: 9.079

4.  Rituximab inefficiency during type I cryoglobulinaemia.

Authors:  H Nehme-Schuster; A-S Korganow; J-L Pasquali; T Martin
Journal:  Rheumatology (Oxford)       Date:  2005-01-18       Impact factor: 7.580

5.  Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil.

Authors:  Douglas E Gladstone; Marc G Golightly; Kenneth W Zamkoff
Journal:  Rheumatol Int       Date:  2005-02-10       Impact factor: 2.631

6.  Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.

Authors:  C Karlsson; S Norin; E Kimby; B Sander; A Porwit Macdonald; B Nilsson; E Johansson; H Mellstedt; J Lundin; A Osterborg
Journal:  Leukemia       Date:  2006-10-19       Impact factor: 11.528

7.  Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.

Authors:  Winnie W Cheung; Gloria Y Hwang; Eric Tse; Yok-Lam Kwong
Journal:  Haematologica       Date:  2006-05       Impact factor: 9.941

8.  Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

Authors:  Holger Nückel; Ulrich H Frey; Alexander Röth; Ulrich Dührsen; Winfried Siffert
Journal:  Eur J Pharmacol       Date:  2005-05-09       Impact factor: 4.432

Review 9.  Management of immune thrombocytopenic purpura in adults.

Authors:  Roberto Stasi; Drew Provan
Journal:  Mayo Clin Proc       Date:  2004-04       Impact factor: 7.616
  9 in total
  1 in total

Review 1.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.